Jun 2, 2022
See the recording of Lytix Biopharma's CMD (June 1st 2022)

Lytix Biopharma hosted a Capital Markets Day for investors, analysts and media on Wednesday, June 1, 2022.

The event was open for physical attendance in Oslo, Norway, as well as a live webcast, and it lastet for two hours, including Q&A.

Speakers was Ted White, CEO of Verrica Pharmaceuticals Inc. (“Verrica”), Gary Goldenberg, CMO of Verrica, Aurelien Marabelle, visiting professor at Stanford University and an internationally recognized expert on intratumoral cancer treatment, and Øystein Rekdal, CEO of Lytix Biopharma.

Verrica has an exclusive worldwide license agreement with Lytix to develop and commercialize its lead compound, LTX-315, for dermatologic oncology conditions, and the first patient has been dosed in Verrica’s Phase II study evaluating LTX-315 for intratumoral treatment of basal cell carcinoma (skin cancer). At the CMD the focus will be on the rationale and current state-of-the-art regarding intratumoral treatment of cancer patients. Most of all, the agreement between Verrica and Lytix and the commercial opportunity for and clinical value of LTX-315 in treatment of cell carcinomas will be highlighted.

See the recording